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that the diagnosis had been made; the number of co-morbid Axis I disorders; the class of prescribed medication for the mental illness; age; race; and gender. The number of subjects who were approached and those who declined to participate were also noted.
The subjects were interviewed in a semi-structured way by asking them the following questions:
• Do you know your diagnosis?
• Do you know what it means?
• Do you know what medication you are on?
• Do you know what the medication is for?
• Do you know what the side-effects of the medications are?
We considered subjects to know their diagnoses even if they did not know the exact names of the diagnoses but knew which clinical phenomena they had been treated for. The diagnoses were categorised in three groups: bipolar disorders; depressive disorders; and psychotic disorders. The medications were grouped as: classic antipsychotic; novel antipsychotic; mood stabiliser; antidepressant (and class of antidepressant); sedative hypnotic; beta-blocker; anticholinergic; and other.
Demographic profile
There were 98 participants of whom 56 (57%) were white, 39 (40%) black, 2 (2%) Indian, and 1 (1%) coloured. There were 50 (51%) males and 48 (49%) females. Two patients declined to take part in the study. The ages of participants ranged from 19 to 78 years, with a standard deviation (SD) of 12 years and a median of 40 years. Fifteen participants had only primary level education and 10 had tertiary level education, with the balance having secondary level education; none of the subjects was illiterate.
Statistical analysis
The Department of Information Technology at the University of Pretoria assisted in the data processing and statistical analysis.
Fisher's exact test and the chi-square test were used for categorical data and variables.
Results
The duration of the subjects' treatment ranged from 6 months to 50 years. The average duration of treatment was 9.3 years, with a SD of 9.2 years. The diagnostic groups were as follows: psychotic disorders: 49 (50%), bipolar disorders: 22 (22%), and depressive disorders: 27 (26%).
All the subjects had poor knowledge of drug side-effects. Twentyeight subjects (29%) knew only the side-effects that they had experienced. Nineteen subjects (19%) gave adequate answers to all study questions except for knowledge of side-effects. They knew their diagnoses, the meaning of their diagnoses, their drug treatment and the purposes of the drugs. Twenty-four (25%) subjects answered all study questions inadequately; they knew neither their diagnoses nor the indications for their treatment nor the names of their medications. The remaining 55 (56%) subjects knew or understood their diagnoses and treatment to some extent, as is summarised in Table I .
Knowledge of diagnosis
Subjects with a mood disorder were more likely to know their diagnosis than subjects with a psychotic disorder. There was a significant statistical association (p=0.094) between diagnosis of a psychotic disorder and diagnosis of a mood disorder, and knowing the diagnosis. There was no significant statistical association (p=0.12) between diagnostic group and knowing what the diagnosis meant. The knowledge that subjects had of their diagnoses and what their diagnoses meant, per diagnostic groups, is summarised in Table II. To evaluate whether having more than one co-morbid Axis I diagnosis influenced the extent of subjects' knowledge, we recorded the number of Axis I diagnoses that subjects had.
Seventy-seven (79%) subjects had only 1 diagnosis; of these, 44 (45%) knew the diagnosis while 39 (40%) knew what they were being treated for.
Twenty-one (21%) subjects had >1 diagnosis. One (1%) subject knew all the diagnoses and their meanings. Eleven (11%) knew 1 diagnosis, and 10 (10%) knew the meaning of the diagnosis.
Nine (9%) knew no diagnosis; 11 (11%) did not know what they were being treated for.
Knowledge of medication
The results indicate that the more drugs a subject was receiving, the less likely they were to know the names of the drugs and their purpose. There was a significant association (p=0.0263) between medication category and knowing the purpose of the medication. Subjects using antipsychotics were less likely to know what their medication was for than subjects in the other medication categories. The extent of the knowledge of subjects taking certain categories of medication of the names of the medication and the reasons for taking the medication is summarised in Table III. concentration difficulties) and drug side-effects (e.g. impaired concentration, interference with memory formation). Lack of insight can also be a contributory factor; a patient may remember the name of the diagnosis but does not accept it and is unwilling articles to attend to information they are given nor try to remember it.
The fact that some patients knew what they were being treated for without knowing the name of the diagnosis also needs explanation.
We offer the following possibilities: the unacceptability of certain diagnoses (e.g. of schizophrenia) may explain why patients with
psychotic disorders knew what they were being treated for (e.g.
for 'voices'), without having known (or having accepted) the term for the disorder. The other possibilities are the same as given in the previous paragraph.
We also suggest a reason why significantly more subjects (57%) knew the names of their medication than why they are taking it (40%): subjects were more often exposed to the name of the 
Conclusion
According to the findings of this study, there is considerable scope for improving the knowledge and understanding of our patients concerning their diagnoses and medication. There could be circumstances where patients would prefer not to have this knowledge, but the previously mentioned literature suggests that it can improve treatment adherence and long-term outcome. [1] [2] [3] [4] [5] [6] [7] [8] The fact that so many patients didn't know why they were taking medication is a plausible explanation for non-compliance and consequent relapse rates. It appears that patients with psychotic disorders, multiple diagnoses and who receive multiple drugs do need special psychoeducational attention.
In view of the limited scope of this study, it can only be viewed as a preliminary effort in this field. The exact reasons for deficiencies in patients' knowledge and understanding need further study in
order to ascertain what can and should be done to improve the situation. We could not find literature that addresses this issue, but it remains the responsibility of the multidisciplinary team to inform patients about their diagnosis and treatment in a clear, understandable and persistent manner, whenever indicated.
